In this study, we investigated the molecular mechanisms underlying adiponectin in MS, finding that the administration of AdipoRon (a small agonist analog of adiponectin) improves neuronal and glial survival and alleviates the viability inhibition that induces MS-CSF administration. Here, ADIPOQ is linked to myeloid sarcoma.